NCT06188975Available不适用
Expanded Access to ABBV-CLS-484
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Available
不适用
Expanded Access to Telisotuzumab AdizutecanNCT05982873AbbVie
No Longer Available
不适用
Expanded Access to ABBV-8E12Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)NCT03744546AbbVie
No Longer Available
不适用
Expanded Access to ABBV-787Acute Myeloid LeukemiaNCT06439966AbbVie
No Longer Available
不适用
Expanded Access to ABT-414Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) DiagnosisNCT03123952AbbVie
No Longer Available
不适用
Expanded Access to VeliparibSolid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically SoundTriple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CancerPatients Requiring Veliparib Suspension FormulationNCT03123211AbbVie